Effects of Ethaverine Hydrochloride on the Walking Tolerance of Patients with Intermittent Claudication

Trainor, Frieda S.; Phillips, Raymond E.; Michie, David D.; Zellner, Stephen R.; Hogan, Jr, Leo; Chubb, James M.
May 1986
Angiology;May1986, Vol. 37 Issue 5, p343
Academic Journal
The effect of ethaverine hydrochloride on excercise tolerance of patients with intermittent claudication was evaluated in a double-blind, placebo-controlled study conducted at three sites. Forty-five patients with symptoms of occlusive arterial insufficiency of the lower extremities were randomly assigned to receive ethaverine 200 mg or placebo four times daily. The patients were evaluated biweekly for 12 weeks with treadmill claudication tests, patient and investigator assessments of symptom severity, and reports of adverse reactions. Doppler ankle/brachial pressure ratios were recorded for 26 patients. Walking tolerance improved for patients in both groups during the course of the study. Increases in distance-to-claudication were significantly greater for patients receiving ethaverine after 6, 8, 10, and 12 weeks of therapy. Ankle/ brachial pressure index after exercise was unchanged in both groups. Incidence of adverse reactions was similar for the two groups. Although patients were generally unaware of any improvement in symptoms, the investigators judged significant relief of claudication among those receiving ethaverine compared to those receiving placebo. It was concluded that ethaverine safely increased distance- to-claudication in patients with intermittent claudication.


Related Articles

  • Naftidrofuryl: A Review of its Use in the Treatment of Intermittent Claudication. Goldsmith, David R.; Wellington, Keri // Drugs & Aging;2005, Vol. 22 Issue 11, p967 

    Naftidrofuryl (Praxilene®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

  • Randomized Reliability Study Evaluating Constant-load and Graded-exercise Treadmill Test for Intermittent Claudication. Cachovan, Milan; Rogatti, Waltraud; Woltering, Franz; Creutzig, Andreas; Diehm, Curt; Heidrich, Heinz; Scheffler, Peter // Angiology;Mar1999, Vol. 50 Issue 3, p193 

    The aim of this randomized study was to compare the reliability of the treadmill test at constant-load (C-test, 3 km/hr; fixed grade of 12%) recommended in Germany with that of the graded-exercise test (G-test, 3 km/hr; increase in grade of 3.5% every 3 minutes) propagated in the United States....

  • Double-Blind Study of Papaverine Hydrochloride on the Efficacy in the Treatment of Intermittent Claudication. Seino, Yoshihiko; Rose, Harold B.; Kanazawa, Masakuni; Vyden, John K.; Wall, Francis J. // Angiology;Apr1983, Vol. 34 Issue 4, p257 

    A double-blind, placebo-controlled, parallel groups study design was utilized to evaluate the efficacy and the safety of papaverine HCL (PA, 300-1,500 mg/day) in the treatment of intermittent claudication. The study was in two phases: Phase 1-6 weeks duration with treadmill claudication tests...

  • Propionyl-l-carnitine for intermittent claudication. Deckert, James // Journal of Family Practice;Jun1997, Vol. 44 Issue 6, p533 

    The article discusses research being done on the effect of propionyl-L-carnitine on the quality of life in intermittent claudication, with reference to a study by G. Brevetti, S. Perna, C. Sabba et al, which appeared in the 1997 issue of the "American Journal of Cardiology." Patients included...

  • Treatment of intermittent claudication. Karthikeyan, G.; Eikelboom, John W. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/21/2009, p671 

    The authors reflect on methods which are used to treat intermittent claudication. They suggest that any methods that are used should improve the patient's symptoms and decrease the risk of cardiovascular problems. They argue that the most important goal of medical treatment in patients with...

  • Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study. Norgren, L; Jawien, A; Mátyás, L; Rieger, H; Arita, K; The European MCI-9042 Study Group // Vascular Medicine;2006, Vol. 11 Issue 2, p75 

    This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent...

  • A Double-Blind, Placebo-Controlled Study of the Effects of Policosanol in Patients with Intermittent Claudication. Castaño, Gladys; Más, Rosa; Roca, Juan; Fernández, Lilia; Illnait, José; Fernandez, Julio César; Selman, Eugenio // Angiology;Feb1999, Vol. 50 Issue 2, p123 

    This study was undertaken to evaluate the efficacy and tolerability of policosanol, a new cholesterol-lowering drug with concomitant antiplatelet effects, in patients with intermittent claudication. After a baseline period of 6 weeks, 62 patients were randomized to receive, under double-blind...

  • Mortality and Morbidity in Patients with Intermittent Claudication in Relation to the Location of the Occlusive Atherosclerosis in the Leg. Tommy Jonason; Ivar Ringqvist // Angiology;May1985, Vol. 36 Issue 5, p310 

    Mortality and morbidity from cerebrovascular and coronary arterial disease over a period of six years were studied in 224 non-diabetic patients with intermittent claudication. Patients with multiple arterial stenoses in the leg had a lower six-year survival than patients with single stenoses...

  • Effects of Pentoxifylline on Severe Intermittent Claudication. Reich, Theobald; Gilings, Dennis // Angiology;Sep1987, Vol. 38 Issue 9, p651 

    Pentoxifylline has been shown to improve treadmill walking distances under blinded, controlled conditions in patients with intermittent claudication. From the pooled data of a blinded, controlled, randomized, multicenter trial, the data from all enrolled patients with severe claudication (< 70 m...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics